Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.

Radial Artery Occlusion Clinical Trial

— DEFINITION  

Official title:

Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04561648
• Other study ID #: INCAR-DG-DI-205-2020
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2020
• Est. completion date: March 1, 2026

Study information

• Verified date: February 2024
• Source: Instituto Nacional de Cardiologia Ignacio Chavez
• Contact: Monserrat Villalobos Pedroza, M.D.
• Phone: 55 5573 2911
• Email: movspa[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Double blind single center clinical trial to compare the incidence of radial artery occlusion (RAO) using standard doses of Unfractionated Heparin (UFH) vs. high doses of UFH.

Description:

Radial artery occlusion (RAO) is one of the most common complications in transradial artery interventions (up to 30% of cases if specific measures are not taken to prevent it) and is related to the prothrombotic state of the patient, the scarce distal flow to the access site and the trauma caused to the artery during the procedure. Currently worldwide, the transradial (TRA) access is the most widely used access for coronary angiography (in up to 90% of the procedures) because the transradial approach is associated with lower rates of vascular complications and event mortality (compared to the femoral access). Although TRA access is safer, it is not free of complications, being one of the most important the RAO. There are universal efforts to reduce RAO improving every aspects of the technique, from the type of introducer to the hemostasis time to a distal TRA, with evidence suggesting that higher doses of UFH can also decrease RAO to a greater extent. The decrease in the incidence of RAO have been proposed to be up to 2.8 times with high doses of UFH (single-center, retrospective study that compared regular not standard doses of UFH versus higher doses of UFH) although no proper prospective clinical trial have been undertaken to prove this. The standard dose that has shown a lower rate of RAO is 5000 IU, which will be compared with 100 IU / Kg of UFH, with a randomized, prospective, double-blind design, with short-term (24-hour) follow-up with Doppler ultrasound (DUS) and its correlation with plethysmography to document RAO, and in occluded arteries, there will be a 30-day follow-up to determine the recanalization (or persistent occlusion) rates by DUS (and plethysmography). In order to address safety concerns of higher UFH doses, all the potential hemorrhagic complications will be evaluated during the study follow-up time and higher hemorrhagic risk patients are going to be excluded.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1988
• Est. completion date: March 1, 2026
• Est. primary completion date: December 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients over 18 years of age, both genders.
• Successful transradial acess for an elective diagnostic coronary angiography.

Exclusion Criteria:

• Weight <50 Kg
• Puncture of the ipsilateral radial artery in the last month.
• Still ongoing effect of pre-procedural recently used oral anticoagulants.
• Use of enoxaparin in the past in the last 12 hours prior to the procedure.
• Use of unfractionated heparin in the last 6 hours prior the procedure
• Alterations in coagulation or platelets prone to bleeding or thrombotic complications.
• Anatomical alterations at the radial access site or radial artery.
• Arteriovenous fistula in the ipsilateral arm.
• History of major bleeding associated with the use of UFH.

Related Conditions & MeSH terms

• Arterial Occlusive Diseases
• Radial Artery Occlusion

Intervention

Drug:
• Unfractionated Heparin
Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.

Locations

Country	Name	City	State
Mexico	Instituto Nacional de Cardiología Ignacio Chávez	Mexico City	Tlalpan

Sponsors (1)

Lead Sponsor	Collaborator
Instituto Nacional de Cardiologia Ignacio Chavez

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radial artery occlusion (RAO).	The incidence of RAO (with DUS and plethysmography).	24 hours.
Primary	Radial artery occlusion (RAO).	The incidence of RAO (with DUS and plethysmography).	30 days.
Secondary	Time to hemostasis.	Time to hemostasis, from the removal of the introducer sheath to hemostasis.	24 hours.
Secondary	Diameters of the radial artery.	Minimum, maximum and mean diameters of the radial artery by vascular ultrasound.	24 hours.
Secondary	Correlation of RAO by oximetric plethysmography and DUS.	Correlation of plethysmography and DUS for the determination of RAO.	30 days.
Secondary	Hemorrhagic Complications.	Compare the incidence of bleeding complications according to The Bleeding Academic Research Consortium 2 (BARC-2) scale: The BARC-2 scale: Type 0; Type 1; Type 2; Type 3; Type 4; Type 5	30 days.
Secondary	Hemorrhagic Complications.	Compare the incidence of bleeding complications according to the Early Discharge After Transradial Stenting of Coronary Arteries Study (EASY) scale: The EASY scale: Grade I; Grade II; Grade III; Grade IV; Grade V	24 hours.